Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharmacol ; 887: 173440, 2020 Nov 15.
Article in English | MEDLINE | ID: mdl-32745603

ABSTRACT

Activation of the voltage-gated Kv7 channels holds therapeutic promise in several neurological and psychiatric disorders, including epilepsy, schizophrenia, and depression. Here, we present a pharmacological characterization of Lu AA41178, a novel, pan-selective Kv7.2-7.5 opener, using both in vitro assays and a broad range of in vivo assays with relevance to epilepsy, schizophrenia, and depression. Electrophysiological characterization in Xenopus oocytes expressing human Kv7.2-Kv7.5 confirmed Lu AA41178 as a pan-selective opener of Kv7 channels by significantly left-shifting the activation threshold. Additionally, Lu AA41178 was tested in vitro for off-target effects, demonstrating a clean Kv7-selective profile, with no impact on common cardiac ion channels, and no potentiating activity on GABAA channels. Lu AA41178 was evaluated across preclinical in vivo assays with relevance to neurological and psychiatric disorders. In the maximum electroshock seizure threshold test and PTZ seizure threshold test, Lu AA41178 significantly increased the seizure thresholds in mice, demonstrating anticonvulsant efficacy. Lu AA41178 demonstrated antipsychotic-like activity by reducing amphetamine-induced hyperlocomotion in mice as well as lowering conditioned avoidance responses in rats. In the mouse forced swim test, a model with antidepressant predictivity, Lu AA41178 significantly reduced immobility. Additionally, behavioral effects typically observed with Kv7 openers was also characterized. In vivo assays were accompanied by plasma and brain exposures, revealing minimum effective plasma levels <1000 ng/ml. Lu AA41178, a potent opener of neuronal Kv7 channels demonstrate efficacy in assays of epilepsy, schizophrenia and depression and might serve as a valuable tool for exploring the role of Kv7 channels in both neurological and psychiatric disorders.


Subject(s)
Brain/drug effects , Disease Models, Animal , KCNQ2 Potassium Channel/agonists , Mental Disorders/drug therapy , Seizures/drug therapy , Animals , Anticonvulsants/pharmacology , Anticonvulsants/therapeutic use , Brain/metabolism , Dose-Response Relationship, Drug , Female , Humans , KCNQ2 Potassium Channel/metabolism , Male , Mental Disorders/metabolism , Mental Disorders/psychology , Mice , Mice, Inbred C57BL , Psychotropic Drugs/pharmacology , Psychotropic Drugs/therapeutic use , Rats , Rats, Wistar , Seizures/metabolism , Seizures/psychology , Treatment Outcome , Xenopus laevis
2.
PLoS One ; 9(6): e100209, 2014.
Article in English | MEDLINE | ID: mdl-24956197

ABSTRACT

The voltage-gated potassium channels of the KV7 family (KV7.1-5) play important roles in controlling neuronal excitability and are therefore attractive targets for treatment of CNS disorders linked to hyperexcitability. One of the main challenges in developing KV7 channel active drugs has been to identify compounds capable of discriminating between the neuronally expressed subtypes (KV7.2-5), aiding the identification of the subunit composition of KV7 currents in various tissues, and possessing better therapeutic potential for particular indications. By taking advantage of the structure-activity relationship of acrylamide KV7 channel openers and the effects of these compounds on mutant KV7 channels, we have designed and synthesized a novel KV7 channel modulator with a unique profile. The compound, named SMB-1, is an inhibitor of KV7.2 and an activator of KV7.4. SMB-1 inhibits KV7.2 by reducing the current amplitude and increasing the time constant for the slow component of the activation kinetics. The activation of KV7.4 is seen as an increase in the current amplitude and a slowing of the deactivation kinetics. Experiments studying mutant channels with a compromised binding site for the KV7.2-5 opener retigabine indicate that SMB-1 binds within the same pocket as retigabine for both inhibition of KV7.2 and activation of KV7.4. SMB-1 may serve as a valuable tool for KV7 channel research and may be used as a template for further design of better subtype selective KV7 channel modulators. A compound with this profile could hold novel therapeutic potential such as the treatment of both positive and cognitive symptoms in schizophrenia.


Subject(s)
KCNQ Potassium Channels , KCNQ2 Potassium Channel , Membrane Transport Modulators/chemistry , Membrane Transport Modulators/pharmacology , Mutation, Missense , Amino Acid Substitution , Animals , Humans , KCNQ Potassium Channels/agonists , KCNQ Potassium Channels/antagonists & inhibitors , KCNQ Potassium Channels/genetics , KCNQ Potassium Channels/metabolism , KCNQ2 Potassium Channel/agonists , KCNQ2 Potassium Channel/antagonists & inhibitors , KCNQ2 Potassium Channel/genetics , KCNQ2 Potassium Channel/metabolism , Xenopus laevis
3.
Anal Biochem ; 418(1): 66-72, 2011 Nov 01.
Article in English | MEDLINE | ID: mdl-21782781

ABSTRACT

To develop a real-time thallium flux assay for high-throughput screening (HTS) of human KCNQ4 (Kv7.4) potassium channel openers, we used CHO-K1 cells stably expressing human KCNQ4 channel protein and a thallium-sensitive dye based on the permeability of thallium through potassium channels. The electrophysiological and pharmacological properties of the cell line expressing the KCNQ4 protein were found to be in agreement with that reported elsewhere. The EC(50) values of the positive control compound (retigabine) determined by the thallium and (86)rubidium flux assays were comparable to and consistent with those documented in the literature. Signal-to-background (S/B) ratio and Z factor of the thallium influx assay system were assessed to be 8.82 and 0.63, respectively. In a large-scale screening of 98,960 synthetic and natural compounds using the thallium influx assay, 76 compounds displayed consistent KCNQ4 activation, and of these 6 compounds demonstrated EC(50) values of less than 20 µmol/L and 2 demonstrated EC(50) values of less than 1 µmol/L. Taken together, the fluorescence-based thallium flux assay is a highly efficient, automatable, and robust tool to screen potential KCNQ4 openers. This approach may also be expanded to identify and evaluate potential modulators of other potassium channels.


Subject(s)
KCNQ Potassium Channels/chemistry , Thallium/chemistry , Animals , CHO Cells , Cricetinae , Drug Evaluation, Preclinical/methods , Fluorescence , High-Throughput Screening Assays , Humans , Ion Channel Gating , KCNQ Potassium Channels/metabolism , Patch-Clamp Techniques , Potassium Channel Blockers/pharmacology , Thallium/metabolism
5.
Org Lett ; 12(12): 2758-61, 2010 Jun 18.
Article in English | MEDLINE | ID: mdl-20462239

ABSTRACT

A Au(I)-catalyzed hydroamination or hydration of 1,3-diynes to access 2,5-diamidopyrroles and 2,5-diamidofurans has been developed. This method can also be expanded to 2,5-disubstituted furans and 1,2,5-trisubstituted pyrroles including the formation of deuterated heterocycles and (18)O-labeled furans.


Subject(s)
Diynes/chemistry , Furans/chemical synthesis , Gold/chemistry , Pyrroles/chemical synthesis , Amination , Catalysis , Combinatorial Chemistry Techniques , Cyclization , Furans/chemistry , Molecular Structure , Pyrroles/chemistry
6.
Org Lett ; 11(18): 4208-11, 2009 Sep 17.
Article in English | MEDLINE | ID: mdl-19697920

ABSTRACT

A highly regioselective hydroamination of unsymmetrical electron-poor and electron-rich alkynes with anilines catalyzed by Au(I) under mild conditions is reported. In addition, applications toward indole syntheses are presented including an example of a one-pot synthesis from a nonfunctionalized aniline.


Subject(s)
Alkynes/chemistry , Aniline Compounds/chemistry , Gold/chemistry , Propionates/chemistry , Catalysis , Combinatorial Chemistry Techniques , Cyclization , Molecular Structure , Stereoisomerism
7.
Org Lett ; 6(12): 1991-4, 2004 Jun 10.
Article in English | MEDLINE | ID: mdl-15176801

ABSTRACT

[reaction: see text] The organometallic intermediate obtained from halogen-metal exchanges of 4-iodo-6-phenylthieno[2,3-d]pyrimidine under Barbier-type conditions was reacted with aldehydes to form the corresponding alcohols in moderate yields. The reaction involving an organolithium intermediate proceeded only at low temperature, whereas the reaction involving a magnesium ate intermediate also proceeded at room temperature. A crystal structure confirms that the expected constitutional alcohol isomer is formed, where no migration has taken place. The conditions were also suitable for 9-benzyl-6-iodopurine.


Subject(s)
Aldehydes/chemical synthesis , Organometallic Compounds/chemistry , Pyrimidines/chemistry , Pyrimidines/chemical synthesis , Aldehydes/chemistry , Models, Chemical , Molecular Structure
9.
Angew Chem Int Ed Engl ; 37(12): 1701-1703, 1998 Jul 03.
Article in English | MEDLINE | ID: mdl-29711506

ABSTRACT

At -40°C aryl iodides that contain other functional groups can be selectively converted into Grignard reagents, which react with electrophiles such as benzaldehyde in the usual manner [Eq. (a)]. Aryl bromides and iodides that are immobilized as esters on a Wang resin behave analogously.

SELECTION OF CITATIONS
SEARCH DETAIL
...